Halobetasol/​Tazarotene

DEA Class; Rx

Common Brand Names; Duobrii

• Antipsoriatics, Topical

Indicated for the treatment of plaque psoriasis.

Pregnancy

• Contact dermatitis (7%)
• Application site pain (3%)
• Folliculitis (2%)
• Skin atrophy (2%)
• Excoriation (2%)
• Rash (1%)
• Skin abrasion (1%)
• Skin exfoliation (1%)

Based on animal reproduction studies, retinoid pharmacology, and potential for systemic absorption, may cause fetal harm when administered to females of reproductive potential and is contraindicated during pregnancy (see Pregnancy)

Local adverse reactions may include atrophy, striae, telangiectasias, folliculitis, and contact dermatitis; if these adverse reactions occur, discontinue treatment at least until integrity of skin is restored; do not resume treatment if allergic contact dermatitis is identified

Avoid use on eczematous skin; may cause severe irritation

Posterior subcapsular cataracts and glaucoma reported postmarketing with topical corticosteroid use

Use appropriate antimicrobial agent if skin infection is present or develops; if favorable response does not occur promptly, discontinue until infection adequately treated

Contraindicated in women who are pregnant

No data available on the presence of tazarotene, halobetasol propionate, or its metabolites in human milk, effects on the breastfed infant, or effects on milk production after treatment

1 application per day topically; 50 grams per week topically.

1 application per day topically; 50 grams per week topically.

Safety and efficacy have not been established.

Safety and efficacy have not been established.

Safety and efficacy have not been established.

Safety and efficacy have not been established.

Halobetasol/tazarotene

topical lotion

• 0.01%/0.045%